DNAemia is essential in clinical management of post-transplant infection. We evaluated the performances of two quantitative real-time polymerase chain reaction (PCR) assays.
Introduction
Cytomegalovirus (CMV) infection remains one of the most common complications after solid organ transplant (SOT), resulting in significant morbidity, graft loss, and occasional mortality. The adverse impact of CMV infection on graft function underscores the importance of CMV on transplant outcomes (10) . Two major strategies are commonly used for prevention of CMV: universal prophylaxis and pre-emptive therapy that have resulted in significant reductions in CMV disease and CMVrelated mortality (10) . Consensus guidelines for the management of CMV infection and disease in SOT recipients have been published (10, 11, 16) . These guidelines recommend the use of quantitative nucleic acid amplification (QNAT)-based assays for CMV as the main choice for diagnosis, making decisions regarding pre-emptive therapy and monitoring response to therapy (3, 4, 8, 9, 12, 17, 18) . However, currently, a universal cut-off for initiating pre-emptive therapy has not been established (10) . In fact, the variability in the performance of different NAT-based assays has been documented and makes it difficult to compare viral load measurements between different laboratories and to develop uniform treatments strategies (14, 19) . These studies have highlighted the need for an internationally accepted reference standard for CMV that has been recently developed (1 st WHO International Standard for human CMV Nucleic Acid Amplification Techniques) (6) . In this study, we evaluated the performances of two commercial available RealTime polymerase chain reaction (PCR) assays − Abbott real-time CMV PCR Kit (Abbott Molecular Inc., Des Plaines, IL, USA) and CMV ELITe MGB™ kit (ELITech Group, Milano, Italy) − for CMV DNA quantitation in whole blood (WB) samples collected by SOT recipients.
Materials and Methods

Clinical samples and artificial standards
A total of 114 serial WB specimens were included in the study. These samples were obtained from 14 selected patients with active CMV infection who had undergone liver (n=4), heart (n=5) and kidney (n=5) transplant at our institution between July 2010 and June 2011. In particular, 35 WB samples were collected from liver, 41 from heart and 3 8 from kidney transplant recipients; the median number of WB samples analysed per patient was equal to 7 (range, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . For all patients, the entire episode of viral replication, preceded and/or followed by at least one WB sample resulted CMV DNA negative with PCR assay routinely used, was analysed. All patients were adults, with a male:female ratio of 9:5 and a mean age of 53 years. Paired CMV serostat uses of Donors (D) and Recipients (R) were D+/R+ in 9 cases, D+/R-in 3 cases, D-/R+ and D-/R-in 1 case, respectively. For these patients, routine follow-up of CMV infection was performed using ELITech PCR assay and peripheral blood samples were collected every week during the first 3 months, then monthly until the sixth month and then every 3 months until one year post-transplant. Additional periphe ral blood samples were taken if clinically indicated. With regard to the clinical management of CMV infection, the following were used: i) prophylaxis therapy with oral valganciclovir (450 mg ×2/day; n=7); ii) pre-emptive therapy with oral valganciclovir (900 mg ×2/day; n=8) or intravenous ganciclovir (10 mg/kg/day; n=1) on the basis of 10,000 CMV DNA copies/mL WB for all the type of SOT; and iii) symptomatic therapy with oral valganciclovir (900 mg ×2/day; n=3).
To compare the two real-time PCR assays, the selected samples stored at −80°C were retrospectively tested using the Abbott realtime CMV PCR Kit. The 2010 quality control for molecular diagnostics (QCMD) human CMV panels (Glasgow, Scotland) were also tested by both real-time PCR assays. This panel consisted of nine samples conta ining various concentrations of CMV strain AD169 in either plasma or in Virus Transport Medium and one plasma sample negative for CMV.
Cytomegalovirus DNA quantitation using CMV ELITe MGB TM kit DNA was extracted from 200 mL of ethylenediaminetetraacetic acid (EDTA)-anticoagulated WB using the QIASymphony SP instrument (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions and eluted in 90 mL. An aliquot of 20 mL of these extracted DNA samples was used for the CMV quantitative real-time PCR on the ABI Prism 7300 RealTime PCR system (PE Applied Biosystem, Foster City, Calif, United States). The same extraction and amplification protocol was used for QCMD panels for human CMV 2010. Primers and probes are located in the highly conserved major immediate early antigen region of the CMV genome. The lower limit of quantification (LLQ) was 225 copies/mL WB; CMV load was reported as numbers of copies/mL.
Cytomegalovirus DNA quantitation using Abbott RealTime CMV PCR Kit
DNA extraction was performed by Abbott mSample Preparation
System DNA kit on the m2000sp instrument coupled with the Abbott CMV PCR kit. DNA was extracted from 300 mL of EDTA-anticoagulated WB and eluted in 250 mL. Afterwards, 35 mL of the eluted samples was tested using the Abbott m2000rt instrument according to the manufacturer's instructions. The same extraction and amplification protocol was used for the 2010 QCMD human CMV panels. The Abbott real-time CMV assay targets two short sequences within the UL34 and UL80.5 genes of the CMV genome. The LLQ was 40 copies/mL WB; CMV load was reported as numbers of copies/mL.
Statistical techniques
The data (in copies/mL) were log10 transformed prior to analysis. Quantitative correlations between the CMV DNA loads obtained using the two methods were evaluated using the Spearman correlation test. The method of Bland and Altman was used to assess the agreement between CMV DNA loads measured using the two assays.
Results
Quality control for molecular diagnostics panel
The 2010 QCMD human CMV panel was used as standard. Each sample was reconstituted by adding 1 mL sterile water as indicated by manufactures guidelines. CMV DNA copies obtained with ELITech and Abbott PCR assays were compared with the consensus values. The results of the evaluation are reported in Table 1 . The negative QCMD control sample was negative in both assay; 1 of the two detected sample (QCMD 10-02, 230 copies/mL) was detected as negative by ELITech assay and except for this result, the values obtained with both assays were within the standard error interval of the consensus values and differed less than 0.5 log10 copies/mL from these reference values.
Clinical samples
A total of 114 serial WB samples collected from 14 selected SOT recipients during episodes of active CMV infection were processed by the two assays. CMV DNA was detected by both assays in 59/114 samples (51.7%), while results were negative in both assays for 16/114 samples (14%). Eleven out of 114 samples (9.6%) tested positive with a quantitative result in the Abbott PCR assay however the results were negative in the ELITech PCR assay. In addition, 16 (14%) positive samples with a quantitative result for Abbott PCR assay resulted positive but below the LLQ for ELITech PCR assay. Furthermore, 12 samples (10.5%) were CMV DNA positive but below the LLQ with the Abbott assay and were negative with ELITech. No samples were positive in the ELITech PCR assay and negative in the Abbott PCR assay. These results are reported in Table 2 .
In the 59 samples with quantitative results by both assays, the coefficient of correlation was equal to 0.856 (Figure 1) .
Bland-Altman analysis showed a mean difference (ELITech-Abbott) of 0.11 log10 copies/mL (standard deviation=0.38 log10 copies/mL). Moreover, ELITech and Abbott PCR assays gave CMV DNA loads differing by less than 1 log10 DNA copies/mL in 57/59 samples (96.6%) and by less than 0.5 log10 DNA copies/mL in 48/59 samples (81.3%) ( Figure 2 ). clinical status and therapeutic strategies were taken in consideration for the interpretation of the results. In Figure 3 , we reported three representative patients of each type of SOT involved. In particular, two episodes of symptomatic CMV reactivation developed during the intermediate (2-6 months) and early (<1 month) post-transplant period in one heart and kidney transplant recipient ( Figure 3A ,C) and a primary CMV infection in a liver transplant recipient ( Figure 3B ) were illustrated. By analysing these patients it is possible to observe that the viral load kinetic profiles of the two assays resulted overlapping and that the Abbott assay showed higher sensitivity in samples containing lower amount of DNA ( Figure 3B ,C).
Clinical follow-up
Patient 1
A 59-year-old male received a heart transplant for ischemic dilated cardiomyopathy in July 2010. The CMV constellation was D+/R+ and the patient received prophylactic valganciclovir (450 mg ×2/day) for 1 month post-transplant. The patient developed symptomatic CMV infection (CMV syndrome) at 163 days post-transplant. CMV infection was successfully treated with oral valganciclovir (900 mg ×2/day). The kinetics of CMV infection showed overlapping patterns with both assay ( Figure 3A ).
Patient 2
A 57-year-old female received a liver transplant for HCV-associated hepatocellular carcinoma in September 2010. CMV serostatus of donor and recipient was D+/R-. The patient received prophylactic valganciclovir (450 mg ×2/day) for 3 months post-transplant; one month later, she seroconverted for CMV without the onset of clinical symptom due to CMV infection. She then received oral valganciclovir (900 mg ×2/day) and pre-emptive therapy was stopped after two consecutive negative results obtained with ELITech assay. Figure 3B summarizes treatment and the kinetics of CMV infection starting 105 days after transplantation. During follow-up, the kinetics of CMV DNA were comparable for the two assays; however, the last two samples (collected at 209 and at 225 days post-transplant) were CMV DNA negative with ELITech and were positive but below the LLQ with the Abbott assay.
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Patient 3
A 50-year-old male received a kidney transplant for glomerulonephritis in January 2011. The recipient and his respective donor were seropositive for CMV at the time of transplantation. As showed in Figure   3C , the patient developed symptomatic CMV infection (fever and neutropenia) at 34 days post-transplant; CMV infection was treated with oral valganciclovir (900 mg ×2/day) and antiviral therapy was stopped after two consecutive negative results obtained with ELITech assay.
Quantitation of CMV DNAemia by both assays starts 20 days posttransplantation. The kinetics of CMV DNA increase were comparable for the two assays, as well as the kinetics of CMV DNA decrease in response to CMV treatment. Discordant results (CMV DNA negative with ELITech and positive but below the LLQ with the Abbott assay) were restricted to the initial and final sampling times of CMV infection (day 20 and 84).
Discussion
CMV infection is an important cause of morbidity and mortality in solid organ transplant recipients, with up to 75% of patients developing or reactivating infection after transplantation (5) . Significant advances have been made in the management of post-transplant CMV infection (10) . The success of CMV prevention during the early post-transplant period and the improvement of CMV disease management are partly attributed to advances in diagnostic virology (4, 15, 16) . Over the years, quantification of CMV load in blood, mostly by real-time PCR, has become a mainstay of clinical management (1) . Nevertheless to date, consensus CMV DNA cut-off values for clinical decision-making, particularly for pre-emptive strategies have not yet been defined, mainly due to the lack of real-time standardization (7) .
In this study, the 2010 QCMD human CMV panels and a total of 114 serial WB samples collected from 14 selected SOT recipients (5 heart, 5 kidney and 4 liver) during episodes of active CMV infection were processed by two commercial available real-time PCR assays, i.e. Abbott and ELITech PCR assays.
The control panel results indicate that the specificity of Abbott and ELITech PCR assays was 100% and the sensitivity was 100% for CMV DNA levels upper to approximately 600 copies/mL (QCMD 10-09, 2.84 log10 copies/mL). Moreover, for the positive samples the two assays provided results less than 0.5 log10 copies/mL difference from the consensus. Therefore, QCMD results showed robustness and accuracy of the two assays.
Regarding the comparison of ELITech and Abbott assays in clinical samples, the two assays showed a good correlation between the samples with measurable DNAemia results. Moreover, CMV DNA quantification in the majority of samples (81.3%) showed a difference <0.5 log10. These results confirm the trend suggested by other studies (13, 14) , according to which 0.5 log10 DNA copies/mL represents the upper limit for divergence from the expected reference values for adequate interlaboratory comparisons of CMV DNA loads with clinical purposes. Most likely, viral load differences of <0.5 log10 when comparing different assays may not be considered clinically relevant and may reflect the intrinsic PCR assay variability (2, 7) . Furthermore, the viral load kinetic profiles of the two assays overlapped in all 14 SOT recipients, but the Abbott assay showed higher sensitivity in samples containing lower amount of DNA. The clinical value of this greater sensitivity therefore requires further investigation. work out the equivalencies between CMV DNA loads measured by different QNAT-based assays, ultimately permitting the establishment of clinically safe CMV DNA thresholds triggering therapeutic intervention. In fact, definition of universal clinically validated thresholds for initiating pre-emptive treatment in solid organ transplant recipients is a major goal in the transplantation setting. 
Conclusions
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